Across 247 CTIS-authorized neurology Phase III trials in Europe, 152 trials used at least one CRO or CRO-like service provider, equal to 61.5% of the cohort. The most active support organizations were IQVIA / Q² Solutions in 60 CRO-supported trials, PPD / Pharmaceutical Product Development in 58, and Clario / ERT / Bioclinica in 50. CRO demand was highest when studies became operationally multi-country: 19 of 19 trials with 11+ countries and 58 of 61 trials with 31+ sites used CRO support.
Among 152 CRO-supported trials, IQVIA / Q² Solutions appeared in 60 trials, PPD / Pharmaceutical Product Development in 58, and Clario / ERT / Bioclinica in 50. The ranking uses grouped CTIS legal entities where the same provider family appeared under multiple names.
The top CRO landscape is not dominated by only one full-service CRO. It combines full-service trial execution providers, central lab / analytics providers, imaging and outcome-assessment vendors, and eClinical platforms, which reflects the operational complexity of late-stage neurology trials.
CRO need was driven more by CTIS/EU country footprint and site network size than by participant volume alone. CRO-supported trials had a median of 6 countries, 23 sites, and 146 planned participants, compared with 1 country, 6 sites, and 88 planned participants in trials without CRO support.
The clearest CRO-demand trigger is EU operational spread. Once a neurology Phase III trial requires parallel CTIS Part II country handling across 6+ countries or coordination across 31+ sites, CRO use becomes the dominant execution model.
Among larger indication groups, myasthenia gravis had the highest CRO-use rate at 13/14 trials, or 92.9%. Multiple sclerosis generated the largest absolute CRO workload, with 24 CRO-supported trials out of 33.
| Indication group | CRO-supported | Rate |
|---|---|---|
| Myasthenia gravis | 13/14 | 92.9% |
| Migraine | 13/16 | 81.3% |
| Alzheimer’s / dementia | 17/23 | 73.9% |
| Multiple sclerosis | 24/33 | 72.7% |
| Epilepsy / seizure disorders | 12/18 | 66.7% |
| Stroke / intracerebral haemorrhage | 8/26 | 30.8% |
CRO demand is strongest in indications that combine specialist neurology assessments, outcome scales, imaging or centralized reading, and multi-country recruitment. Multiple sclerosis is the largest addressable CRO workload; myasthenia gravis and migraine show the highest CRO adoption rates.
The most common outsourced functions in CRO-supported trials were central laboratory, bioanalysis, or pharmacokinetic services in 129/152 trials, imaging / ECG / central clinical reading in 113/152, and patient recruitment, retention, reimbursement, travel, or home-health support in 86/152.
Neurology Phase III outsourcing is not just site monitoring. The dominant demand sits in specialized infrastructure: central labs, imaging and ECG interpretation, outcome scales, eCOA/PRO platforms, patient-support logistics, and CTIS/EC operational support for multi-country execution.
Pharmaceutical-company sponsors used CROs in 146/165 neurology Phase III trials, or 88.5%. Hospital and healthcare sponsors used CROs in only 1/66 trials, or 1.5%. CRO-supported trials accounted for 950/1,087 CTIS country participations and 4,156/5,001 listed sites.
| Top country in CRO-supported trials | Trial-country participations | Sites |
|---|---|---|
| Spain | 114 | 702 |
| Italy | 113 | 646 |
| Germany | 96 | 520 |
| Poland | 93 | 587 |
| France | 84 | 445 |
CRO need is concentrated where commercial sponsors are managing broad European execution. Spain, Italy, Germany, Poland, and France form the largest CTIS/site workload cluster for CRO-supported neurology Phase III trials.
CRO-supported trials were much more likely to use digital recruitment or remote participant-support components: 67/152 CRO-supported trials used digital recruitment signals, compared with 2/95 non-CRO trials. Registry or advocacy recruitment appeared in 31/152 CRO-supported trials versus 3/95 non-CRO trials.
| Signal | CRO-supported | No CRO |
|---|---|---|
| Digital recruitment / remote support | 67/152, 44.1% | 2/95, 2.1% |
| Registry / advocacy recruitment | 31/152, 20.4% | 3/95, 3.2% |
| Randomised design | 115/152, 75.7% | 58/95, 61.1% |
| Adaptive design | 13/152, 8.6% | 1/95, 1.1% |
Digital recruitment, advocacy involvement, randomized design, and adaptive design all skew toward CRO-supported trials. These are useful early signals for identifying neurology Phase III protocols that may require external operating infrastructure before CTIS/EU submission and country activation.
CRO means contract research organization or CTIS-listed trial-support provider. CTIS means Clinical Trials Information System, the EU clinical trial submission and authorization portal. eCOA means electronic clinical outcome assessment. IRT means interactive response technology used for randomisation, treatment assignment, and trial-supply workflows.